膀胱がん分子病理学診断の世界市場規模・現状・予測2021年-2027年

QYResearchが発行した調査報告書(QY21JNE1916)
◆英語タイトル:Global Bladder Cancer Molecular Diagnostics Market Size, Status and Forecast 2021-2027
◆商品コード:QY21JNE1916
◆発行会社(リサーチ会社):QYResearch
◆発行日:2021年6月(※2024年版があります。お問い合わせください。)
◆ページ数:98
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査資料では、膀胱がん分子病理学診断の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(PCR、FISH、DNAシーケンシング、ジーンチップ)、用途別市場規模(臨床診断、薬物スクリーニング、研究所)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・膀胱がん分子病理学診断の市場動向
・企業の競争状況、市場シェア
・膀胱がん分子病理学診断の種類別市場規模(PCR、FISH、DNAシーケンシング、ジーンチップ)
・膀胱がん分子病理学診断の用途別市場規模(臨床診断、薬物スクリーニング、研究所)
・膀胱がん分子病理学診断の北米市場規模2016-2027(アメリカ、カナダ)
・膀胱がん分子病理学診断の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・膀胱がん分子病理学診断のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・膀胱がん分子病理学診断の中南米市場規模2016-2027(メキシコ、ブラジル)
・膀胱がん分子病理学診断の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(Genetech、Gpmedical、Gene+、DMDbiomed、Annoroad、Topgen、Geneis、Unitedgene、Inmedi)
・結論
【レポートの概要】

A molecular approach for diagnosing bladder cancer

Market Analysis and Insights: Global Bladder Cancer Molecular Diagnostics Market
The global Bladder Cancer Molecular Diagnostics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Bladder Cancer Molecular Diagnostics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Bladder Cancer Molecular Diagnostics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Bladder Cancer Molecular Diagnostics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Bladder Cancer Molecular Diagnostics market.

Global Bladder Cancer Molecular Diagnostics Scope and Market Size
Bladder Cancer Molecular Diagnostics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Bladder Cancer Molecular Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
PCR
FISH
DNA Sequencing
Gene Chip

Segment by Application
Clinical Diagnosis
Drug Screening
Research

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Genetech
Gpmedical
Gene+
DMDbiomed
Annoroad
Topgen
Geneis
Unitedgene
Inmedi

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Bladder Cancer Molecular Diagnostics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 PCR
1.2.3 FISH
1.2.4 DNA Sequencing
1.2.5 Gene Chip
1.3 Market by Application
1.3.1 Global Bladder Cancer Molecular Diagnostics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Clinical Diagnosis
1.3.3 Drug Screening
1.3.4 Research
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Bladder Cancer Molecular Diagnostics Market Perspective (2016-2027)
2.2 Bladder Cancer Molecular Diagnostics Growth Trends by Regions
2.2.1 Bladder Cancer Molecular Diagnostics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Bladder Cancer Molecular Diagnostics Historic Market Share by Regions (2016-2021)
2.2.3 Bladder Cancer Molecular Diagnostics Forecasted Market Size by Regions (2022-2027)
2.3 Bladder Cancer Molecular Diagnostics Industry Dynamic
2.3.1 Bladder Cancer Molecular Diagnostics Market Trends
2.3.2 Bladder Cancer Molecular Diagnostics Market Drivers
2.3.3 Bladder Cancer Molecular Diagnostics Market Challenges
2.3.4 Bladder Cancer Molecular Diagnostics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Bladder Cancer Molecular Diagnostics Players by Revenue
3.1.1 Global Top Bladder Cancer Molecular Diagnostics Players by Revenue (2016-2021)
3.1.2 Global Bladder Cancer Molecular Diagnostics Revenue Market Share by Players (2016-2021)
3.2 Global Bladder Cancer Molecular Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Bladder Cancer Molecular Diagnostics Revenue
3.4 Global Bladder Cancer Molecular Diagnostics Market Concentration Ratio
3.4.1 Global Bladder Cancer Molecular Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Bladder Cancer Molecular Diagnostics Revenue in 2020
3.5 Bladder Cancer Molecular Diagnostics Key Players Head office and Area Served
3.6 Key Players Bladder Cancer Molecular Diagnostics Product Solution and Service
3.7 Date of Enter into Bladder Cancer Molecular Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Bladder Cancer Molecular Diagnostics Breakdown Data by Type
4.1 Global Bladder Cancer Molecular Diagnostics Historic Market Size by Type (2016-2021)
4.2 Global Bladder Cancer Molecular Diagnostics Forecasted Market Size by Type (2022-2027)

5 Bladder Cancer Molecular Diagnostics Breakdown Data by Application
5.1 Global Bladder Cancer Molecular Diagnostics Historic Market Size by Application (2016-2021)
5.2 Global Bladder Cancer Molecular Diagnostics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Bladder Cancer Molecular Diagnostics Market Size (2016-2027)
6.2 North America Bladder Cancer Molecular Diagnostics Market Size by Type
6.2.1 North America Bladder Cancer Molecular Diagnostics Market Size by Type (2016-2021)
6.2.2 North America Bladder Cancer Molecular Diagnostics Market Size by Type (2022-2027)
6.2.3 North America Bladder Cancer Molecular Diagnostics Market Size by Type (2016-2027)
6.3 North America Bladder Cancer Molecular Diagnostics Market Size by Application
6.3.1 North America Bladder Cancer Molecular Diagnostics Market Size by Application (2016-2021)
6.3.2 North America Bladder Cancer Molecular Diagnostics Market Size by Application (2022-2027)
6.3.3 North America Bladder Cancer Molecular Diagnostics Market Size by Application (2016-2027)
6.4 North America Bladder Cancer Molecular Diagnostics Market Size by Country
6.4.1 North America Bladder Cancer Molecular Diagnostics Market Size by Country (2016-2021)
6.4.2 North America Bladder Cancer Molecular Diagnostics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Bladder Cancer Molecular Diagnostics Market Size (2016-2027)
7.2 Europe Bladder Cancer Molecular Diagnostics Market Size by Type
7.2.1 Europe Bladder Cancer Molecular Diagnostics Market Size by Type (2016-2021)
7.2.2 Europe Bladder Cancer Molecular Diagnostics Market Size by Type (2022-2027)
7.2.3 Europe Bladder Cancer Molecular Diagnostics Market Size by Type (2016-2027)
7.3 Europe Bladder Cancer Molecular Diagnostics Market Size by Application
7.3.1 Europe Bladder Cancer Molecular Diagnostics Market Size by Application (2016-2021)
7.3.2 Europe Bladder Cancer Molecular Diagnostics Market Size by Application (2022-2027)
7.3.3 Europe Bladder Cancer Molecular Diagnostics Market Size by Application (2016-2027)
7.4 Europe Bladder Cancer Molecular Diagnostics Market Size by Country
7.4.1 Europe Bladder Cancer Molecular Diagnostics Market Size by Country (2016-2021)
7.4.2 Europe Bladder Cancer Molecular Diagnostics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Bladder Cancer Molecular Diagnostics Market Size (2016-2027)
8.2 Asia-Pacific Bladder Cancer Molecular Diagnostics Market Size by Type
8.2.1 Asia-Pacific Bladder Cancer Molecular Diagnostics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Bladder Cancer Molecular Diagnostics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Bladder Cancer Molecular Diagnostics Market Size by Type (2016-2027)
8.3 Asia-Pacific Bladder Cancer Molecular Diagnostics Market Size by Application
8.3.1 Asia-Pacific Bladder Cancer Molecular Diagnostics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Bladder Cancer Molecular Diagnostics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Bladder Cancer Molecular Diagnostics Market Size by Application (2016-2027)
8.4 Asia-Pacific Bladder Cancer Molecular Diagnostics Market Size by Region
8.4.1 Asia-Pacific Bladder Cancer Molecular Diagnostics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Bladder Cancer Molecular Diagnostics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Bladder Cancer Molecular Diagnostics Market Size (2016-2027)
9.2 Latin America Bladder Cancer Molecular Diagnostics Market Size by Type
9.2.1 Latin America Bladder Cancer Molecular Diagnostics Market Size by Type (2016-2021)
9.2.2 Latin America Bladder Cancer Molecular Diagnostics Market Size by Type (2022-2027)
9.2.3 Latin America Bladder Cancer Molecular Diagnostics Market Size by Type (2016-2027)
9.3 Latin America Bladder Cancer Molecular Diagnostics Market Size by Application
9.3.1 Latin America Bladder Cancer Molecular Diagnostics Market Size by Application (2016-2021)
9.3.2 Latin America Bladder Cancer Molecular Diagnostics Market Size by Application (2022-2027)
9.3.3 Latin America Bladder Cancer Molecular Diagnostics Market Size by Application (2016-2027)
9.4 Latin America Bladder Cancer Molecular Diagnostics Market Size by Country
9.4.1 Latin America Bladder Cancer Molecular Diagnostics Market Size by Country (2016-2021)
9.4.2 Latin America Bladder Cancer Molecular Diagnostics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Bladder Cancer Molecular Diagnostics Market Size (2016-2027)
10.2 Middle East & Africa Bladder Cancer Molecular Diagnostics Market Size by Type
10.2.1 Middle East & Africa Bladder Cancer Molecular Diagnostics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Bladder Cancer Molecular Diagnostics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Bladder Cancer Molecular Diagnostics Market Size by Type (2016-2027)
10.3 Middle East & Africa Bladder Cancer Molecular Diagnostics Market Size by Application
10.3.1 Middle East & Africa Bladder Cancer Molecular Diagnostics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Bladder Cancer Molecular Diagnostics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Bladder Cancer Molecular Diagnostics Market Size by Application (2016-2027)
10.4 Middle East & Africa Bladder Cancer Molecular Diagnostics Market Size by Country
10.4.1 Middle East & Africa Bladder Cancer Molecular Diagnostics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Bladder Cancer Molecular Diagnostics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Genetech
11.1.1 Genetech Company Details
11.1.2 Genetech Business Overview
11.1.3 Genetech Bladder Cancer Molecular Diagnostics Introduction
11.1.4 Genetech Revenue in Bladder Cancer Molecular Diagnostics Business (2016-2021)
11.1.5 Genetech Recent Development
11.2 Gpmedical
11.2.1 Gpmedical Company Details
11.2.2 Gpmedical Business Overview
11.2.3 Gpmedical Bladder Cancer Molecular Diagnostics Introduction
11.2.4 Gpmedical Revenue in Bladder Cancer Molecular Diagnostics Business (2016-2021)
11.2.5 Gpmedical Recent Development
11.3 Gene+
11.3.1 Gene+ Company Details
11.3.2 Gene+ Business Overview
11.3.3 Gene+ Bladder Cancer Molecular Diagnostics Introduction
11.3.4 Gene+ Revenue in Bladder Cancer Molecular Diagnostics Business (2016-2021)
11.3.5 Gene+ Recent Development
11.4 DMDbiomed
11.4.1 DMDbiomed Company Details
11.4.2 DMDbiomed Business Overview
11.4.3 DMDbiomed Bladder Cancer Molecular Diagnostics Introduction
11.4.4 DMDbiomed Revenue in Bladder Cancer Molecular Diagnostics Business (2016-2021)
11.4.5 DMDbiomed Recent Development
11.5 Annoroad
11.5.1 Annoroad Company Details
11.5.2 Annoroad Business Overview
11.5.3 Annoroad Bladder Cancer Molecular Diagnostics Introduction
11.5.4 Annoroad Revenue in Bladder Cancer Molecular Diagnostics Business (2016-2021)
11.5.5 Annoroad Recent Development
11.6 Topgen
11.6.1 Topgen Company Details
11.6.2 Topgen Business Overview
11.6.3 Topgen Bladder Cancer Molecular Diagnostics Introduction
11.6.4 Topgen Revenue in Bladder Cancer Molecular Diagnostics Business (2016-2021)
11.6.5 Topgen Recent Development
11.7 Geneis
11.7.1 Geneis Company Details
11.7.2 Geneis Business Overview
11.7.3 Geneis Bladder Cancer Molecular Diagnostics Introduction
11.7.4 Geneis Revenue in Bladder Cancer Molecular Diagnostics Business (2016-2021)
11.7.5 Geneis Recent Development
11.8 Unitedgene
11.8.1 Unitedgene Company Details
11.8.2 Unitedgene Business Overview
11.8.3 Unitedgene Bladder Cancer Molecular Diagnostics Introduction
11.8.4 Unitedgene Revenue in Bladder Cancer Molecular Diagnostics Business (2016-2021)
11.8.5 Unitedgene Recent Development
11.9 Inmedi
11.9.1 Inmedi Company Details
11.9.2 Inmedi Business Overview
11.9.3 Inmedi Bladder Cancer Molecular Diagnostics Introduction
11.9.4 Inmedi Revenue in Bladder Cancer Molecular Diagnostics Business (2016-2021)
11.9.5 Inmedi Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

...

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 膀胱がん分子病理学診断の世界市場規模・現状・予測2021年-2027年(Global Bladder Cancer Molecular Diagnostics Market Size, Status and Forecast 2021-2027)]についてメールでお問い合わせはこちらでお願いします。